Literature DB >> 8302077

Survival related to nodal status after sleeve resection for lung cancer.

R J Mehran1, J Deslauriers, M Piraux, M Beaulieu, C Guimont, J Brisson.   

Abstract

Sleeve lobectomy is a lung-saving procedure indicated for central tumors for which the alternative is a pneumonectomy. The relation between survival and nodal status is controversial because, in most series, the presence of N1 disease adversely affects the prognosis with few or no long-term survivors. During the period 1972 to 1992, 142 patients underwent sleeve resection for lung cancer at our institution. Mean age (+/- standard deviation) was 60.7 +/- 9.1 years (range 11 to 78 years), and indications for operation were a central tumor in 112 patients (79%), a peripheral tumor in 18 patients (13%), and compromised pulmonary function in 12 patients (8%). Histologic type was predominantly squamous (72.5%) followed by nonsquamous (24.6%) and carcinoid tumors (2.8%). Resection was complete in 124 patients (87%) and incomplete in 18 (13%), and the operative mortality was 2.1% (n = 3). Follow-up was complete for the 139 remaining patients. Including operative deaths, survivals at 5 and 10 years for all patients were 46% (95% confidence intervals 38% to 55%) and 33% (95% confidence intervals 24% to 42%), respectively. For patients with N0 status (n = 73), 5- and 10-year survivals were 57% (95% confidence intervals 45% to 69%) and 46% (95% confidence intervals 32% to 60%); for patients with N1 status (n = 55), these rates were 46% (95% confidence intervals 32% to 60%) and 27% (95% confidence intervals 14% to 40%) (p = 0.13). No patient with N2 status (n = 14) survived 5 years. Local recurrences occurred in 23% of cases, but the prevalence was not statistically different between patients with N0 disease (16.6%) and N1 disease (23.1%) (p = 0.43). These data suggest that sleeve resection is an adequate operation for patients with resectable lung cancer and N0 N1 status. The presence of N2 disease significantly worsens the prognosis and may contraindicate the use of the procedure.

Entities:  

Mesh:

Year:  1994        PMID: 8302077

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival.

Authors:  Mark F Berry; Mathias Worni; Xiaofei Wang; David H Harpole; Thomas A D'Amico; Mark W Onaitis
Journal:  Ann Thorac Surg       Date:  2013-11-06       Impact factor: 4.330

2.  Comparison of surgical outcomes after pneumonectomy and pulmonary function-preserving surgery for non-small cell lung cancer.

Authors:  Mitsunori Higuchi; Hironori Takagi; Yuki Ozaki; Takuya Inoue; Yuzuru Watanabe; Takumi Yamaura; Mitsuro Fukuhara; Satoshi Muto; Naoyuki Okabe; Yuki Matsumura; Takeo Hasegawa; Jun Osugi; Mika Hoshino; Yutaka Shio; Hiroyuki Suzuki
Journal:  Fukushima J Med Sci       Date:  2018-02-20

3.  Characteristics of tumor extension requiring bronchoplasty and pneumonectomy in patients with lung cancer and positive bronchoscopic findings.

Authors:  Yasuo Sekine; Yukio Saitoh; Masako Chiyo; Kazuhiro Yasufuku; Akira Iyoda; Kiyoshi Shibuya; Toshihiko Iizasa; Takehiko Fujisawa
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Comparison of operative mortality and complications between bronchoplastic lobectomy and pneumonectomy in lung cancer patients.

Authors:  Eung-Sirk Lee; Seung-Il Park; Yong Hee Kim; Chi Hoon Bae; Hye Won Moon; Mi Sun Chun; Dong Kwan Kim
Journal:  J Korean Med Sci       Date:  2007-02       Impact factor: 2.153

5.  Sleeve lobectomy compared with pneumonectomy for operable centrally located non-small cell lung cancer: a meta-analysis.

Authors:  Zhengjun Li; Wei Chen; Mozhu Xia; Hongxu Liu; Yongyu Liu; Ilhan Inci; Fabio Davoli; Ryuichi Waseda; Pier Luigi Filosso; Abby White
Journal:  Transl Lung Cancer Res       Date:  2019-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.